Evaluation of BI 770371 and Pembrolizumab, With or Without Cetuximab, Versus Pembrolizumab Monotherapy in Head and Neck Squamous Cell Carcinoma Patients

The primary objective of this study is to evaluate the efficacy of **BI 770371** in combination with **pembrolizumab**, with or without **cetuximab**, in patients with **head and neck squamous cell carcinoma** compared to pembrolizumab alone. This is clinically relevant as it aims to determine whether the combination therapy can improve treatment outcomes for patients with this type of cancer, potentially offering a more effective therapeutic option.

The clinical trial involves a total of **56 participants** diagnosed with **head and neck squamous cell carcinoma**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion criteria.

The clinical trial is designed to evaluate the efficacy of **BI 770371** in combination with pembrolizumab, with or without cetuximab, compared to pembrolizumab alone in patients with **head and neck squamous cell carcinoma**. This is a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is February 17, 2025, with an anticipated end date of March 30, 2028. The trial will involve multiple study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Participants who meet the inclusion criteria will be randomly assigned to one of the treatment groups.

Throughout the trial, participants will attend regular follow-up visits to monitor treatment efficacy and safety. These visits will include assessments such as physical examinations, laboratory tests, and imaging studies. The purpose of these visits is to ensure participant safety and to collect data on the primary and secondary endpoints of the study. The end-of-study visit will occur after the final treatment cycle, where comprehensive evaluations will be conducted to assess the overall outcomes of the trial.

The expected length of participant involvement in the study is approximately three years, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or any other medical reasons deemed necessary by the investigator. Participants will be closely monitored throughout the trial to ensure adherence to the protocol and to address any issues that may arise during the study period.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on February 17, 2025, with an estimated completion date of March 30, 2028. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the available data. The trial will follow a structured methodology to ensure the accurate measurement and analysis of efficacy parameters. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy outcomes.